MedWatch

Swiss pharmaceutical company could launch the first EU treatment for rare disease

The European Medicines Agency (EMA) has approved of the drug Revestive for the treatment of SBS in adults.

The Swiss company Nycomed has taken a big step closer to marketing their drug Revestive for the treatment of adult patients with SBS, or short bowel syndrome, in Europe, after the EMA has recommended the approval of the drug to the European Commision, according to Dagens Pharma.

Nycomed is thus ready to launch the first medical treatment of this rare, but seriously debilitating condition in Europe.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier